331 related articles for article (PubMed ID: 33030673)
1. Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.
Bahmad HF; Chalhoub RM; Harati H; Bou-Gharios J; Assi S; Ballout F; Monzer A; Msheik H; Araji T; Elajami MK; Ghanem P; Chamaa F; Kadara H; Abou-Antoun T; Daoud G; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):211-226. PubMed ID: 33030673
[TBL] [Abstract][Full Text] [Related]
2. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells.
Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W
Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310
[TBL] [Abstract][Full Text] [Related]
3. Tideglusib suppresses stem-cell-like features and progression of osteosarcoma by inhibiting GSK-3β/NOTCH1 signaling.
Wei D; Zhu X; Li S; Liu G; Wang Y; Wang W; Zhang Q; Jiang S
Biochem Biophys Res Commun; 2021 May; 554():206-213. PubMed ID: 33813076
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.
Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M
BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783
[TBL] [Abstract][Full Text] [Related]
5. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.
Bayat Mokhtari R; Baluch N; Ka Hon Tsui M; Kumar S; S Homayouni T; Aitken K; Das B; Baruchel S; Yeger H
BMC Cancer; 2017 Feb; 17(1):156. PubMed ID: 28235409
[TBL] [Abstract][Full Text] [Related]
6. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line.
Dickey A; Schleicher S; Leahy K; Hu R; Hallahan D; Thotala DK
J Neurooncol; 2011 Aug; 104(1):145-53. PubMed ID: 21161565
[TBL] [Abstract][Full Text] [Related]
7. XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1.
Tian X; Hou W; Bai S; Fan J; Tong H; Xu H
Int J Oncol; 2014 Jul; 45(1):121-8. PubMed ID: 24789807
[TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth.
Kroon J; in 't Veld LS; Buijs JT; Cheung H; van der Horst G; van der Pluijm G
Oncotarget; 2014 Oct; 5(19):8986-94. PubMed ID: 25344861
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
[TBL] [Abstract][Full Text] [Related]
10. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
11. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
12. POTEE stimulates the proliferation of pancreatic cancer by activating the PI3K/Akt/GSK-3β/β-catenin signaling.
Hao Q; Gao L; Niu W; Chen L; Zhang P; Chen Z
Biofactors; 2020 Jul; 46(4):685-692. PubMed ID: 32589786
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells.
Li Z; Tan F; Thiele CJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3113-21. PubMed ID: 18089706
[TBL] [Abstract][Full Text] [Related]
14. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
Ugolkov AV; Bondarenko GI; Dubrovskyi O; Berbegall AP; Navarro S; Noguera R; O'Halloran TV; Hendrix MJ; Giles FJ; Mazar AP
Anticancer Drugs; 2018 Sep; 29(8):717-724. PubMed ID: 29846250
[TBL] [Abstract][Full Text] [Related]
15. GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Abrams SL; Akula SM; Meher AK; Steelman LS; Gizak A; Duda P; Rakus D; Martelli AM; Ratti S; Cocco L; Montalto G; Cervello M; Ruvolo P; Libra M; Falzone L; Candido S; McCubrey JA
Cells; 2021 Apr; 10(4):. PubMed ID: 33917370
[TBL] [Abstract][Full Text] [Related]
16. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
17. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.
Yu AS; Zhao L
Tumour Biol; 2016 Apr; 37(4):4857-64. PubMed ID: 26526575
[TBL] [Abstract][Full Text] [Related]
18. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
19. Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation.
Mathuram TL; Ravikumar V; Reece LM; Karthik S; Sasikumar CS; Cherian KM
Environ Toxicol Pharmacol; 2016 Sep; 46():194-205. PubMed ID: 27490211
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ
J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
